The MedicX Fund Limited Scrip Dividend Alternative - Suspension (2495I)

TIDMMXF

RNS Number : 2495I

The MedicX Fund Limited

22 November 2018

22 November 2018

MedicX Fund Limited

("MedicX", "the Fund" or "the Company")

Scrip Dividend Alternative - Suspension

Further to the Company's announcement on 1 November 2018, in which the Directors declared a quarterly dividend of 1.51p per Ordinary Share in respect of the period 1 July 2018 to 30 September 2018 (the "December 2018 Dividend"), the Board of Directors notes that the Scrip Calculation Price in respect of that dividend is less than the prevailing EPRA Net Asset Value per ordinary share.

The Board believes that it would not be in the best interests of the Company, and of shareholders as a whole, to offer a scrip dividend alternative in such circumstances. Accordingly, all shareholders entitled to receive the December 2018 Dividend will do so in cash.

The suspension of the scrip dividend alternative relates solely to the December 2018 Dividend, with the Board continuing to consider the availability of scrip in respect of any future dividends on a case-by-case basis.

End

For further information please contact:

   Octopus Healthcare Adviser Ltd                                     [phone] 
   Octopus Healthcare                                                      [phone] 

Mike Adams, Executive Chairman

   Maitland/AMO                                                              [phone] 

Andy Donald/Freddie Barber

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 165 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over GBP1.4 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages GBP8.0 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 320,000 customers.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCPGGRCGUPRGCP

(END) Dow Jones Newswires

November 22, 2018 10:00 ET (15:00 GMT)